63 results about "Thymidine" patented technology

The invention discloses a Cb Ago-based TdT detection reagent and a Cb Ago-based TdT detection method. The TdT detection reagent comprises a TdT extension reaction system and a TdT detection system, wherein the TdT extension reaction system comprises a TdT reaction buffer solution, deoxythymidine triphosphate, cobalt ions and an extension reaction detection probe; the Cb Ago system comprises Cb Ago, a Cb Ago buffer solution and a fluorescence report probe. The extension reaction detection probe disclosed by the invention can extend under the action of TdT, and then is in specific complementary pairing with the fluorescent reporter probe to activate Cb Ago to cut the fluorescent reporter probe, so that TdT detection is realized. The high specificity of the TdT extension reaction and the signal amplification capacity of Cb Ago are combined, and the method has the advantages of being easy and convenient to operate, high in sensitivity, low in cost, suitable for on-site detection and the like and is expected to become a powerful tool for detecting TdT.

There is provided a method for diagnosing a subject with early onset muscle atrophy, said method comprising: obtaining a biosample from the subject; and assaying the biosample for one or more biomarkers, said one more biomarkers are taurine, proline, citrulline, trigonelline, thymidine, ornithine, glutamate, L-pyroglutamic acid, creatinine, adenine, nicotinamide, 2-methylhippuric acid, maltol, L-arginine, hypotaurine, L-glutamine, homogentisic acid, methylhistidine, oxoglutaric acid, xanthine, L-carnitine, succinate, or a combination thereof; and identifying the subject with early onset muscle atrophy on the basis of a deviation in the one or more of said one more biomarkers.

The invention provides a method for improving the bioavailability of a nucleoside drug for treating mitochondrial depletion syndrome. In particular, the methods involve increasing the bioavailability of deoxycytidine and deoxythymidine by administering a therapeutically effective amount of deoxycytidine and deoxythymidine with food.

This invention discloses a trimethyl chitosan-hyaluronic acid-FMNL2 siRNA nanomedicine and its applications. The siRNA molecule consists of a sense strand and an antisense strand, which are anti-complementary to form a double-stranded RNA structure. Each of the sense and antisense strands independently contains two pendant deoxythymidines at its 3' end. The nanomedicine uses trimethyl chitosan as its core framework, efficiently encapsulating the siRNA molecule through electrostatic interactions, and then modifying hyaluronic acid through electrostatic interactions to form core-shell structured nanoparticles. This invention forms a complete technology chain from target validation, siRNA sequence design, nanodelivery system construction, in vivo and in vitro efficacy verification to the development of combination drug strategies. It also provides quantifiable efficacy evaluation biomarkers, offering a clear basis for clinical patient screening and efficacy monitoring.

Provided herein are methods of treating a cancer, comprising administering to a patient diagnosed with cancer an effective amount of a thymidine analog and a thymidylate synthase inhibitor, wherein the thymidine analog incorporates into DNA.

The invention belongs to the technical field of preparation of molecular identification, adsorption and separation functional materials, and discloses a method for preparing a bowl-shaped imprinted polymer adsorbent by inducing silicon-based imprinted liquid drops through an asymmetric effect and application of the bowl-shaped imprinted polymer adsorbent. The preparation method comprises the following steps: by taking 9-vinyl adenine 9-VA as a functional monomer and beta-thymidine as a functional monomer, pre-assembling, and then forming silicon-based imprinting liquid drops with hydrolyzed 3-(trimethoxysilyl) propyl methacrylate; then synthesizing ellipsoidal iron oxide particles, modifying the surfaces of the ellipsoidal iron oxide particles by using PVP (Polyvinyl Pyrrolidone), taking the modified ellipsoidal iron oxide particles as seeds, and polymerizing the seeds with the hydrolyzed silicon-based imprinting liquid drops under the condition of magnetic stirring; under the action of centrifugal force, the mass of the iron oxide particles is far greater than that of the polymer liquid drops, under the action of asymmetric force, the iron oxide particles drag the polymer liquid drops to deform to form large recesses, AIBN is added to initiate polymerization and curing, and the composite bowl-shaped imprinted polymer particles containing the iron oxide particles are prepared; the method is used for realizing high-selectivity adsorption separation of dT.

This disclosure relates to the modified 3' region elements that confer improved therapeutic properties including, but not limited to, increased stability, increased expression, and / or a reduced innate immune response when introduced into a population of cells, even in the absence of a 5'-cap. The disclosure also provides polynucleotides (e.g., RNA molecules) containing modified 3' regions. In some embodiments of the disclosure, the modified 3' regions contain modified adenosines (e.g., 2'-0-methoxy- adenosine, 2'-fluoro-adenosine, or locked nucleic acid (LNA)-adenosine) and / or a modified thymidine (e.g., inverted deoxythymidine). In some embodiments of the disclosure, the modified 3' region may contain one or more modified internucleoside linkages (e.g., a phosphorothioate linkage) or modified nucleobase (e.g., N1-methyl-pseudouridine). The polynucleotides of the disclosure may be used to express a desired polypeptide in a subject, such as a subject having a disease or condition associated with a deficiency in the corresponding endogenous polypeptide.

Compounds, compositions, and methods of treatment and prevention of HIV, including HIV-1 and HIV-2, Dengue, and Chikungunya infection are disclosed. The compounds are TREM-1 inhibitors. Combinations of these TREM-1 inhibitors and additional antiretroviral compounds, such as NRTI, NNRTI, integrase inhibitors, entry inhibitors, protease inhibitors, JAK inhibitors, macrophage depleting agents, and the like, are also disclosed. In one embodiment, the combinations include a combination of adenine, cytosine, thymidine, and guanine nucleoside antiviral agents, optionally in further combination with at least one additional antiviral agent that works via a different mechanism than a nucleoside analog. This combination has the potential to eliminate the presence of HIV, Dengue, or Chikungunya virus in an infected patient.

The application provides an immune cell culture kit, a culture method and application of gamma delta T cells, and the kit comprises a basic culture medium, a recombinant antibody, a cytokine and a cell proliferation promoting additive, the basic culture medium comprises an RPMI-1640 culture medium, and the cell proliferation promoting additive comprises 1-thioglycerol, taurine, beta-cyclodextrin, thymidine, alpha-lipoic acid, beta-mercaptoethanol and bisphosphonate. The gamma delta T cells obtained by the culture kit have high purity and activity, and have good tumor killing activity. The gamma delta T cells obtained by the method have a high positive rate of 100% of perforin expression.

The application discloses a HAT probe with adjustable switch characteristics and application thereof, which comprises a secondary structure capable of forming specific steric hindrance, the secondary structure is a convex "bubble" or "ring", and the core of the secondary structure is a polydeoxythymidine sequence with a length of 5-30 nucleotides. The HAT probe has a "switch" regulation function: a molecular switch is constructed by utilizing the inhibition and activation of Cas12a activity of the complete structure and the linear structure after cutting of the HAT probe. The "switch" can respond to specific biomolecules (such as miRNA, protein), and convert the existence of the biomolecules into a detectable signal.

The invention relates to the technical field of medicines, in particular to a borate compound as well as a preparation method and application thereof. Wherein the structural formula of the boric acid ester compound is as shown in I. According to the invention, through molecular structure design, 3-carboxyl is utilized for modification, water solubility and intramolecular hydrogen bonds are enhanced, hydrolysis is inhibited, and stability is improved; a uracil structure is utilized, thymidine / deoxyuridine is simulated, the thymidine / deoxyuridine is actively taken by TK1 high-expression cancer cells and is enriched near DNA in a targeted manner, the BNCT efficiency is improved, and a novel boron drug with high water solubility, stability and targeting property is successfully developed. # imgabs0 #

Methods and formulations are provided for treating cancer and neoplastic diseases in conjunction with radiation therapy where such methods and formulations include a combination of a radiosensitizing agent that is metabolized by thymidine phosphorylase and a thymidine phosphorylase inhibitor that increases the half-life of the radiosensitizing agent.

The invention relates to high-purity thymine, a process of purification of thymine, a process for preparing high-purity deoxythymidine, pharmaceutical compositions containing high-purity deoxythymidine and deoxycytidine as well as their use as pharmaceuticals for treatment of mitochondrial depletion syndromes in a mammal.

The present invention provides a method for determining the prognosis of an individual having cancer and being considered for treatment with one or more immune checkpoint inhibitors or currently being treated with one or more immune checkpoint inhibitors, the method comprises or consists of the steps of: a) providing a sample obtained from the individual prior to treatment with one or more immune checkpoint inhibitors; b) measuring the activity and / or concentration of thymidine kinase (TK) in said sample; c) providing a sample obtained from the individual 1-4 weeks after a first treatment with the one or more immune checkpoint inhibitors; and d) measuring the activity and / or concentration of thymidine kinase (TK) in said sample provided in step (c); wherein the activity and / or concentration of thymidine kinase (TK) measured in steps (b) and (d) is indicative of a prognosis of the individual if further treated with one or more immune checkpoint inhibitors.

The invention discloses thymine-containing polyolefin as well as a preparation method and application thereof, the structural formula of the polyolefin is shown in the specification, x is equal to 100-400, and R is phenyl. Norbornene monomer NBT containing nuclear basic groups is synthesized and is copolymerized with cyclooctene (COE) through ring-opening metathesis polymerization (ROMP), and long-chain alkane is introduced to improve the toughness of the polymer; and a series of polymers with ultra-high molecular weight are synthesized by changing the proportion. The NBT in the polymer enables the polymer to have good hydrophobic performance, and the NBT as a hot melt adhesive has good adhesion performance to different substrates.

The invention provides a culture medium suitable for fermentation of Ralstonia solanacearum bacteriophage, a culture method and application. The culture medium comprises thymidine and L-tryptophan. The culture medium provided by the invention can realize more effective culture and fermentation of Ralstonia solanacearum bacteriophage, improves the titer of bacteriophage fermentation liquor in a tank, and has the advantages of simple preparation method, more scientific components and suitability for industrial production.

Compounds, compositions, and methods of treatment and prevention of HIV infection are disclosed. The compounds are pyrrolo[2,3-b]pyridines and pyrrolo[2,3-b]pyrimidine JAK inhibitors. Combinations of these JAK inhibitors and additional antiretroviral compounds, such as NRTI, NNRTI, integrase inhibitors, entry inhibitors, protease inhibitors, and the like, are also disclosed. In one embodiment, the combinations include a combination of adenine, cytosine, thymidine, and guanine nucleoside antiviral agents, optionally in further combination with at least one additional antiviral agent that works via a different mechanism than a nucleoside analog. This combination has the potential to eliminate the presence of HIV in an infected patient.

The invention relates generally to a pharmacological therapy for human genetic diseases, specifically those characterized by unbalance nucleotide pools, more specifically mitochondrial DNA depletion syndromes, and more specifically, thymidine kinase 2 (TK2) deficiency. The pharmacological therapy involves the administration of at least one deoxynucleoside, or mixtures thereof. For the treatment of TK2 deficiency, the pharmacological therapy involves the administration of either deoxythymidine (dT) or deoxycytidine (dC), or mixtures thereof. This administration of deoxynucleosides is applicable to other disorders of unbalanced nucleotide pools, especially those found in mitochondrial DNA depletion syndrome.

The present disclosure provides pyrimidine nucleoside compounds, including torcitabine, thymidine, deoxyuridine, deoxycytidine and uridine, and methods to treat telomere biology disorders (TBDs) and aging-related diseases, including hematological disorder, liver disease, or hepatic fibrosis, comprising administering to a subject diagnosed with said telomere biology disorder a therapeutically effective amount of said compounds.

Compounds, compositions, and methods of treatment and prevention of HIV infection are disclosed. The compounds are pyrrolo[2,3-b]pyridines and pyrrolo[2,3-b]pyrimidine JAK inhibitors. Combinations of these JAK inhibitors and additional antiretroviral compounds, such as NRTI, NNRTI, integrase inhibitors, entry inhibitors, protease inhibitors, and the like, are also disclosed. In one embodiment, the combinations include a combination of adenine, cytosine, thymidine, and guanine nucleoside antiviral agents, optionally in further combination with at least one additional antiviral agent that works via a different mechanism than a nucleoside analog. This combination has the potential to eliminate the presence of HIV in an infected patient.

The invention discloses a heterologous transport protein YdhP and application thereof in production of beta-thymidine from escherichia coli, and belongs to the technical field of microbial engineering. According to the present invention, by introducing the heterologous transport protein ydhP derived from Ralstania mannitolyticus, the extracellular secretion of beta-thymidine can be effectively promoted, and the intracellular feedback regulation limitation can be reduced; during shake flask fermentation, the yield of beta-thymidine is increased to 1.6 g / L (increased by about 45%), and the by-product deoxyuridine is reduced by about 50%; the yield in a 5 L fermentation tank reaches 20 g / L, which is obviously improved compared with that of a control strain (12 g / L), and an efficient and stable engineering strain and a fermentation process are provided for industrial production of beta-thymidine.

The invention belongs to the technical field of nucleoside medicine preparation, and particularly discloses a method for efficiently preparing 2-deoxy-D-ribose. According to the method, reactants are added into Escherichia coli fermentation liquor for recombinant expression of thymidine phosphorylase, and acid hydrolysis treatment is carried out after one-step catalytic reaction to directly generate 2-deoxy-D-ribose. The method can be used for catalytically preparing the high-concentration 2-deoxy-D-ribose, so that the production of the 2-deoxy-D-ribose reaches a kilogram level, and large-scale industrialization is realized. The preparation process disclosed by the invention does not need to purify recombinase, is simple, saves cost, saves energy, reduces emission, reduces equipment investment, and further reduces production cost.

The invention provides a preparation method and application of deoxyadenosine, and relates to the technical field of biology. The preparation method of the deoxyadenosine provided by the invention comprises the following steps: mixing beta-thymidine, adenine, Tt pyrimidine nucleoside phosphorylase and Apmtap purine nucleoside phosphorylase in a buffer solution, and carrying out an enzyme catalytic reaction to prepare the deoxyadenosine, the amino acid sequence of the Tt pyrimidine nucleoside phosphorylase is as shown in SEQ ID NO. 1; the amino acid sequence of the Apmtap purine nucleoside phosphorylase is as shown in SEQ ID NO. 2; the temperature of the catalytic reaction is 60-90 DEG C, and the pH value is 6.5-7.5. The preparation method is simple in process, mild in reaction condition, green, environment-friendly and high in product conversion rate, and can be used for industrial production.

The invention discloses a method for improving L-lactic acid synthesized by thermoanaerobacter thermosaccharolyticus, and belongs to the technical field of genetic engineering. According to the invention, a thymidine kinase gene tdk, a phosphate acetyltransferase-acetokinase gene ptaack, an ethanol dehydrogenase gene adhE, a methylglyoxal synthase gene mgs, a lactic acid racemase race1 and a lactic acid racemase race2 are knocked out, so that the thermoanaerobacter thermolyticus engineering bacterium with high yield of L-lactic acid and reduced by-product accumulation is constructed. The thermoanaerobacter thermolyticus engineering bacterium can be used for producing L-lactic acid with high optical purity through fermentation by taking straw sugar as a carbon source, and has industrial application potential.

Provided is a method for increasing the bioavailability of nucleoside drugs in the treatment of mitochondrial depletion syndrome. In particular, the method relates to increasing the bioavailability of deoxycytidine and deoxythymidine by administering a therapeutically effective amount of deoxycytidine and deoxythymidine with food.

The present application provides compositions and methods for preparing and using “heavy” nucleotide derivatives of thymidine or uridine by replacing the oxygen atom attached to one or more of positions with non-radioactive oxygen-18 (18O), administering it to a subject to target a tumor including incorporation into tumor cell DNA, and then treating the tumor with proton beam therapy to transmutate the 18O to 18F, resulting in a break of the new fluorine-phosphorous bond. This chemical event destabilizes ribose-phosphate DNA back-bone and base pairing thus produce single- and double strand breaks, clusters lesions that can lead to irreparable DNA damage and enhanced tumor cell killing. The atomic, chemical, and physical aspects result in the use of lower radiation doses and significantly alter acute and late morbidity of radiotherapy. Heavy thymidine and heavy uridine derivatives labeled with 18O have been made and tested.

The invention relates to C2 '-alkyl substituted nucleoside which comprises at least one of C2'-alkyl substituted thymidine, C2 '-alkyl substituted uridine, C2'-alkyl substituted adenosine and C2 '-alkyl substituted guanosine. The structure of the C2 '-alkyl substituted nucleoside is shown as a formula I or a formula II; the structure of the C2 '-alkyl substituted uridine is shown as a formula III in the specification; the structure of the C2 '-alkyl substituted adenosine is shown as a formula IV; the structure of the C2 '-alkyl substituted guanosine is shown as a formula V. The invention also relates to a preparation method of the C2 '-alkyl substituted nucleoside. According to the C2 '-alkyl substituted nucleoside and the preparation method thereof, the limitation of the prior art on functional group compatibility and operation convenience can be broken through, and the synthesis path of the C2'-alkyl substituted nucleoside can be enriched, so that the research and development process of oligonucleotide drugs is greatly promoted.

The present invention relates generally to the fields of cancer cell biology, cancer therapeutics for cancers located within in the central nervous system, thymidine analogs and cellular nucleotide excision repair mechanisms. More specifically, the invention relates to the use of EdU in methods of treating cancers located within in the central nervous system, and methods of inhibiting and / or reducing growth of a cancer or cancer cell.

The invention discloses an aptamer-mediated proximity marker probe, a method and a cell membrane protein interaction analysis method. The proximity marker probe comprises an aptamer targeting a target protein; the tail end of the 5'end of the nucleic acid aptamer is connected with a spacer arm composed of N thymine, the tail end of the spacer arm is modified with alkynyl, the thymine close to the tail end of the spacer arm is modified with biotin, and N is an integer larger than or equal to 2. The method disclosed by the invention has the advantages of high specificity, simplicity in operation, capability of accurately controlling the marking range and the like.

The present invention provides substituted 2 ', 3'-didehydro-3 '-deoxy-4'-ethynyl thymidine and related compounds, pharmaceutical compositions, their use for inhibiting LINE1 reverse transcriptase activity, their use for inhibiting HERV-K reverse transcriptase activity, and their use in the treatment of medical conditions such as cancer.